| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yoo Young-Ho CEO | KRX SM Exchange | KR7068760008 ISIN |
| South Korea Country | - Employees | 29 Dec 2025 Last Dividend | 27 Dec 2024 Last Split | - IPO Date |
Celltrion Pharm, Inc. is a prominent pharmaceutical company based in Cheongju-si, South Korea, with a robust history dating back to its founding in 1976. This innovative company specializes in the development and sales of biosimilars and over-the-counter (OTC) drugs within the South Korean market. Celltrion Pharm, Inc. plays a crucial role in the healthcare industry by offering a wide range of therapeutic solutions designed to meet diverse medical needs, including hepatotonic, anti-inflammatory, antihistamine, respiratory, circulatory system, digestive and stomachic treatments. Moreover, the company’s portfolio extends to hormone/metabolic disease therapies, antibiotic/antimycotic medications, nutrientia and tonics, as well as products geared towards immunology and oncology. By serving key healthcare institutions such as university hospitals, along with general pharmacies, Celltrion Pharm, Inc. demonstrates its commitment to enhancing public health through the provision of high-quality pharmaceutical products.
Celltrion Pharm, Inc. offers an extensive array of products and services aimed at improving patient care through innovative pharmaceutical solutions: